Nuzyra Now Available in IV, Oral Forms for CABP, ABSSSI 6 Feb 2019 5:00 AM (6 years ago)
Nuzyra, an aminomethylcycline (related to tetracycline antibiotics), is designed to overcome tetracycline resistance and has broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria, and other drug-resistant strains.
Pexidartinib Gets Priority Review for Tenosynovial Giant Cell Tumor 6 Feb 2019 4:00 AM (6 years ago)
The NDA is supported by data from the Phase 3 ENLIVEN study (N=120) which randomized patients with symptomatic TGCT to receive pexidartinib or placebo to evaluate the safety and efficacy of the treatment.
Alyq, a Generic Version of PAH Treatment Adcirca, Now Available 6 Feb 2019 3:30 AM (6 years ago)
Alyq should not be used with concomitant organic nitrates or guanylate cyclase (GC) stimulators (eg, riociguat), and in patients with a known serious hypersensitivity to tadalafil.
Compounded Pain Creams Evaluated in Patients With Localized Chronic Pain 5 Feb 2019 10:00 AM (6 years ago)
To investigate the effectiveness of compounded creams in the treatment of chronic pain conditions, study authors performed a double-blind, randomized, parallel study comparing creams compounded with an active ingredient to placebo creams.
Clinician Sued for Wrongful Death After Overlooking Drug Allergy in Medical Record 5 Feb 2019 9:00 AM (6 years ago)
The patient had a history of asthma, COPD, diabetes and severe anaphylactic reactions to multiple medicines.
ACIP Updates Recommendations for US Adult Immunization Schedule 5 Feb 2019 8:00 AM (6 years ago)
The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.
FDA to Review Two Antibacterial Agents for Potentially Life-Threatening Infections 5 Feb 2019 8:00 AM (6 years ago)
Both filings have been granted Priority Review by the Agency.
Novel Glioblastoma Treatment Granted Orphan Drug Designation 5 Feb 2019 5:56 AM (6 years ago)
In preclinical models, the inhibition of phosphorylated STAT3 (p-STAT3) by WP1066 resulted in the direct attack of various tumor cells.
FDA to Review Cenobamate for the Treatment of Partial-Onset Seizures 4 Feb 2019 10:00 AM (6 years ago)
While the exact mechanism of action of cenobamate is not fully understood, it is believed to work through a dual mechanism.
Yutiq Now Available for Chronic Non-Infectious Posterior Segment Uveitis 4 Feb 2019 7:30 AM (6 years ago)
It is designed to release fluocinolone acetonide, a corticosteroid, at an initial rate of 0.25mcg/day.